Novo Nordisk (NOVO_B) Licenses HRS-1596 In Deal Worth Up To $2.6B

Novo Nordisk entered an exclusive license with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP agonist, including $300M upfront and up to $2.6B in milestones. Rights cover all markets except mainland China, Hong Kong, Macao and Taiwan.Material DetailsContext by AI AnalystThi…